← Back to Search

Neurokinin Antagonist

Tradipitant Low Dose for Motion Sickness

Phase 3
Recruiting
Research Sponsored by Vanda Pharmaceuticals
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 day
Awards & highlights

Study Summary

"This trial will study the effectiveness of tradipitant in reducing motion sickness in travelers. It will be a blinded study conducted at multiple centers."

Who is the study for?
This trial is for people aged 18-75 who often get motion sickness when traveling. It's not suitable for those with a BMI over 40, other nausea-causing conditions, or past bad reactions to Neurokinin-1 Receptor blockers.Check my eligibility
What is being tested?
The study tests Tradipitant against a placebo to see if it helps prevent travel-related motion sickness. Participants are randomly assigned to either the drug or placebo group without knowing which one they're getting.See study design
What are the potential side effects?
Tradipitant may cause side effects like headache, drowsiness, dry mouth, and in rare cases allergic reactions. The exact side effects will be monitored throughout the trial.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 day
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 day for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Prevention of vomiting measured by Vomiting Assessment (VA)

Side effects data

From 2019 Phase 3 trial • 375 Patients • NCT03568331
4%
Headache
4%
Upper respiratory tract infection
3%
Diarrhoea
2%
Dermatitis atopic
1%
Dyshidrotic eczema
1%
Choking
100%
80%
60%
40%
20%
0%
Study treatment Arm
Tradipitant
Placebo

Trial Design

3Treatment groups
Experimental Treatment
Placebo Group
Group I: Tradipitant Low DoseExperimental Treatment1 Intervention
Group II: Tradipitant High DoseExperimental Treatment1 Intervention
Group III: PlaceboPlacebo Group1 Intervention
Oral Capsule
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Tradipitant
2016
Completed Phase 3
~1090

Find a Location

Who is running the clinical trial?

Vanda PharmaceuticalsLead Sponsor
61 Previous Clinical Trials
19,104 Total Patients Enrolled
3 Trials studying Motion Sickness
1,015 Patients Enrolled for Motion Sickness
~164 spots leftby Jun 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top